The value of PET ligand discovery to CNS drug development

Future Med Chem. 2017 Mar;9(4):351-356. doi: 10.4155/fmc-2017-0018. Epub 2017 Mar 6.

Authors

Mark E Schmidt¹, José Ignacio Andrés²

Affiliations

¹ Neuroscience Therapeutic Area, Janssen Research & Development, Division of Janssen Pharmaceutica, NV, Turnhoutseweg 30, Beerse 2340, Belgium.
² Discovery Sciences, Janssen Research & Development, Janssen-Cilag S. A., C/Jarama 75A, 45007 Toledo, Spain.

PMID: 28263084
DOI: 10.4155/fmc-2017-0018

No abstract available

Keywords: Alzheimer's disease; CNS drug development; PET; positron emission tomography.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Central Nervous System Agents / chemical synthesis
Central Nervous System Agents / chemistry
Central Nervous System Agents / pharmacology*
Central Nervous System Diseases / diagnosis*
Central Nervous System Diseases / drug therapy*
Drug Discovery*
Humans
Ligands
Positron-Emission Tomography*

Substances

Central Nervous System Agents
Ligands